On June 17, Chief scientist Professor Wang Jianxun went to the National Clinical Medical Research Center of Kidney Diseases, Eastern Theater General Hospital to visit and exchange, and had an in-depth discussion with Academician Liu Zhihong's team on the clinical research and application of cell therapy in kidney disease. Our senior research and development scientist Dr. Fu Yuchen accompanied.
Professor Zhihong Liu is an academician of the Chinese Academy of Engineering, a member of the Faculty of the Chinese Academy of Medical Sciences, an executive director of the Council of the Chinese Medical Association, the ninth chairman of the Chinese Society of Nephrology, an executive director of the International Society of Nephrology (ISN), and the director of the National Clinical Medical Research Center for Kidney Diseases of the Eastern Theater General Hospital. And has undertaken a number of national key scientific research projects, including the national "973" plan project, the National "precision Medicine" key research and development plan project, the National Natural Science Foundation major international cooperation project, the National Natural Science Foundation major project, and has rich experience in scientific research and clinical practice.



Under the guidance of Professor Zhang Haitao, deputy director of the National Center, and Professor Huang Xianghua, director of the Cell Therapy Center of the Institute, Professor Wang Jianxun and his delegation visited the building of the National Center, including specimen bank, outpatient clinic, clinical experiment center, clinical laboratory, cell therapy center, intensive care unit, key laboratory and so on.


 

At the symposium, both sides conducted in-depth and detailed discussions on the clinical research and practical application of cell therapy in the field of kidney disease. Professor Wang Jianxun said that in recent years, China's cell immunotherapy has developed rapidly, at present, Shenzhen Cell Valley has established close cooperation with a number of well-known hospitals at home and abroad, providing gene and non-gene modified immune cell preparation services for clinical treatment, and with advanced research and development technology, excellent preparation quality and significant therapeutic effect, has been highly recognized by the industry. Ensure that the scientific research results of independent research and development truly serve the clinical needs and are widely used in clinical practice.
Academician Liu Zhihong pointed out that the National Kidney Disease Center has accumulated rich experience in immunization and cell therapy, and its technology transformation work is closely based on the clinical platform, showing excellent practical ability. At the same time, Academician Liu Zhihong spoke highly of the product technology of Shenzhen Cell Valley and believed that it has the potential to play an important role in the field of kidney disease treatment. He hoped that both sides could focus on multiple diseases and jointly promote the clinical research and application progress of kidney disease cell therapy under the premise of ensuring the effectiveness and safety of treatment.
The exchange visit promoted further cooperation between Shenzhen Cell Valley and the National Clinical Medical Research Center for Kidney Diseases, and the two sides will jointly explore new paths for cell therapy in the field of kidney disease, bringing safer and more effective treatment options for kidney patients.

The nephrology Department of the Eastern Theater General Hospital is one of the earliest established nephrology departments in China. The department established the first nephrology center of the Army in 1986. At present, it is not only the Institute of Nephrology of the Army, but also the key clinical specialty of the army. It is also the Jiangsu Translational Medicine Center of Kidney Disease, Jiangsu Clinical Medical Research Center of Kidney Disease, Jiangsu Medical Innovation Center and national clinical key specialty, and was approved as the first national clinical medical research center of kidney disease in China in 2013. After more than 40 years of hard work and continuous innovation under the leadership of Academician Liu Zhihong, director of the Center, it has developed into a world-renowned, domestic, modern management and distinctive specialty of kidney disease, and has won a wide academic reputation for its high-quality clinical services, superb medical technology, fruitful innovation results and rigorous work style. The discipline has been ranked among the top of the "Best Discipline Reputation List of Chinese Hospitals" by Fudan University for many consecutive years, and the nephropathy department has been ranked the first in the "National Hospital Internet Influence List", serving tens of millions of patients with kidney disease.